首页> 外文OA文献 >Chemotherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study

【2h】

Chemotherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study

机译：化疗耐药作为卵巢癌患者新辅助化疗和手术细胞减少后腹膜内化疗后无进展生存期的预测指标：西南肿瘤小组研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Tiersten, Amy D.; Moon, James; Smith, Harriet O.; Wilczynski, Sharon P.; Robinson, 3rd, William R.; Markman, Maurie; Alberts, David S.;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
中文文献
专利

1. Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group Study. [J] . Tiersten AD, Moon J, Smith H Oncology: International Journal of Cancer Research and Treatment . 2009,第6期

机译：西南肿瘤小组研究：在新辅助化疗和手术细胞减少后再进行腹膜内化疗治疗的卵巢癌患者中，化疗耐药是无进展生存的预测指标。
2. Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group Study. [J] . Tiersten AD, Moon J, Smith H Oncology: International Journal of Cancer Research and Treatment . 2009,第6期

机译：作为卵巢癌患者的无进展生存期的化疗抗性，并用新辅助化疗和外科患者进行，随后是腹膜内化疗：西南肿瘤学群体研究。
3. Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group Study. [J] . Tiersten AD, Moon J, Smith H Oncology: International Journal of Cancer Research and Treatment . 2009,第6期

机译：作为卵巢癌患者的无进展生存期的化疗抗性，并用新辅助化疗和外科患者进行，随后是腹膜内化疗：西南肿瘤学群体研究。
4. Surgical Cytoreduction Could Improve the Effects of Chemotherapy After Operation and Maintain the QOL of Patients with Advanced Gastric Cancer [C] . A. Ishiguro, M. Munakata, Y. Sakat International Gastric Cancer Congress . 2005

机译：手术细胞凝固可以改善化疗后的疗法疗法，并维持晚期胃癌患者的QoL
5. Predicting chemotherapy resistance in breast cancer patients using radiofluorinated analogues of chemotherapy agents in conjunction with positron emission tomography. [D] . Kesner, Amanda Lovell. 2003

机译：结合使用化疗剂的放射性氟化类似物和正电子发射断层扫描术，可以预测乳腺癌患者的化疗耐药性。
6. Chemotherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study [O] . Amy D. Tiersten, James Moon, Harriet O. Smith, -1

机译：化疗耐药作为卵巢癌患者新辅助化疗和手术细胞减少后腹膜内化疗后无进展生存期的预测指标：西南肿瘤小组研究
7. Weekly induction intraperitoneal chemotherapy after primary surgical cytoreduction in patients with advanced epithelial ovarian cancer [O] . 2006

机译：晚期上皮性卵巢癌患者原发性手术减量后每周诱导腹膜内化疗

Chemotherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study

著录项

相似文献

相关主题

期刊订阅